Proposal to fund prasugrel tablets

Overview

We are proposing to fund prasugrel tablets (5 mg and 10 mg) in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 February 2027 for use in both the community and Health New Zealand | Te Whatu Ora (Health NZ) hospitals. 

Prasugrel, used in combination with aspirin, helps prevent blood clots and associated cardiovascular events including heart attack, stroke and cardiovascular death, in people with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention (PCI), such as coronary angioplasty or stent placement. 

If approved, prasugrel 5 mg and 10 mg tablets would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 February 2027.